IN2015DN01738A - - Google Patents

Download PDF

Info

Publication number
IN2015DN01738A
IN2015DN01738A IN1738DEN2015A IN2015DN01738A IN 2015DN01738 A IN2015DN01738 A IN 2015DN01738A IN 1738DEN2015 A IN1738DEN2015 A IN 1738DEN2015A IN 2015DN01738 A IN2015DN01738 A IN 2015DN01738A
Authority
IN
India
Prior art keywords
irbesartan
coa reductase
reductase inhibitor
hmg coa
independent
Prior art date
Application number
Inventor
Yong Il Kim
Yoeng Jin Kwon
Caleb Hyungmin Park
Seung Yeop Lee
Jae Hyun Park
Jong Soo Woo
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50183919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2015DN01738(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of IN2015DN01738A publication Critical patent/IN2015DN01738A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Disclosed are a pharmaceutical composite capsule formulation comprising 1) an independent irbesartan unit comprising irbesartan or a pharmaceutically acceptable salt thereof; and 2) an independent HMG CoA reductase inhibitor unit comprising an HMG CoA reductase inhibitor or a pharmaceutically acceptable salt thereof and an alkaline additive wherein said independent units are separated from each other within a capsule and a method for preparing the same. Designed to prevent an interaction between irbesartan and the HMG CoA reductase inhibitor the pharmaceutical composite capsule formulation is improved in stability and dissolution rate and thus shows great bioavailability. In addition the formulation is expected to guarantee high drug compliance owing to its small size and therefore can be applied to the treatment of hypertension and hypercholesterolemia.
IN1738DEN2015 2012-08-31 2013-08-30 IN2015DN01738A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020120096036A KR20140030505A (en) 2012-08-31 2012-08-31 Pharmaceutical composite capsule formulation comprising irbesartan and hmg-coa reductase inhibitor
PCT/KR2013/007841 WO2014035190A1 (en) 2012-08-31 2013-08-30 Pharmaceutical composite capsule formulation comprising irbesartan and hmg-coa reductase inhibitor

Publications (1)

Publication Number Publication Date
IN2015DN01738A true IN2015DN01738A (en) 2015-05-29

Family

ID=50183919

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1738DEN2015 IN2015DN01738A (en) 2012-08-31 2013-08-30

Country Status (28)

Country Link
US (1) US20150231085A1 (en)
EP (1) EP2890371A4 (en)
JP (1) JP2015526509A (en)
KR (1) KR20140030505A (en)
CN (1) CN104602678A (en)
AR (1) AR092385A1 (en)
AU (1) AU2013309688A1 (en)
BR (1) BR112015004091A2 (en)
CA (1) CA2882738A1 (en)
CL (1) CL2015000363A1 (en)
CO (1) CO7350622A2 (en)
CR (1) CR20150124A (en)
DO (1) DOP2015000042A (en)
EA (1) EA201590474A1 (en)
EC (1) ECSP15010617A (en)
IL (1) IL237425A0 (en)
IN (1) IN2015DN01738A (en)
MA (1) MA37953A1 (en)
MX (1) MX2015002591A (en)
NI (1) NI201500028A (en)
PE (1) PE20150402A1 (en)
PH (1) PH12015500395A1 (en)
RU (1) RU2015111523A (en)
SG (1) SG11201500580QA (en)
TW (1) TW201414511A (en)
UY (1) UY35000A (en)
WO (1) WO2014035190A1 (en)
ZA (1) ZA201502157B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101771766B1 (en) * 2013-12-30 2017-08-28 알보젠코리아 주식회사 Pharmaceutical combination comprising Angiotensin-Ⅱ Receptor Blocker and HMG-CoA Reductase Inhibitor
EP3184103A1 (en) * 2015-12-21 2017-06-28 Hexal AG Pharmaceutical composition comprising atorvastatin or a salt thereof
WO2019023198A1 (en) * 2017-07-25 2019-01-31 Plexxikon Inc. Formulations of a compound modulating kinases
CN110237070A (en) * 2019-05-10 2019-09-17 辽宁大学 Application of irbesartan in the preparation of blood lipid-lowering drugs
WO2023080910A1 (en) * 2020-11-18 2023-05-11 Fb-Hrs, Llc Compositions containing dofetilide and mexiletine and uses thereof
CN113476423A (en) * 2021-07-05 2021-10-08 海南通用三洋药业有限公司 Preparation method of rosuvastatin calcium capsule and rosuvastatin calcium capsule

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI20109A (en) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stable pharmaceutical formulation
PE20030324A1 (en) * 2001-07-31 2003-04-03 Warner Lambert Co PHARMACEUTICAL COMPOSITIONS OF AMLODIPINE AND ATORVASTATIN
AU2005249794A1 (en) * 2004-06-04 2005-12-15 Teva Pharmaceutical Industries, Ltd. Pharmaceutical composition containing irbesartan
WO2008010008A2 (en) * 2006-07-17 2008-01-24 Wockhardt Limited Cardiovascular combinations using rennin-angiotensin inhibitors
US20110212175A1 (en) * 2006-10-30 2011-09-01 Hanall Biopharma Co., Ltd. Combination preparation comprising angiotensin-ii-receptor blocker and hmg-coa reductase inhibitor
CA2720800C (en) * 2008-03-28 2013-07-30 Ferrer Internacional S.A. Capsule for the prevention of cardiovascular diseases
KR101205633B1 (en) * 2008-04-29 2012-11-27 한올바이오파마주식회사 Pharmaceutical formulation for treating cardiovascular disease
NZ596064A (en) * 2009-04-30 2014-03-28 Reddy’S Lab Ltd Dr Fixed dose drug combination formulations
KR101248804B1 (en) * 2010-05-14 2013-03-29 한미사이언스 주식회사 BILAYERED PHARMACEUTICAL COMPOSITION OF HMG-CoA REDUCTASE INHIBITOR AND IRBESARTAN
US9056134B2 (en) * 2010-07-21 2015-06-16 Nucitec S.A. De C.V. Single daily dosage form for prevention and treatment of metabolic syndrome

Also Published As

Publication number Publication date
PH12015500395A1 (en) 2015-04-27
UY35000A (en) 2014-03-31
CO7350622A2 (en) 2015-08-10
DOP2015000042A (en) 2015-04-30
CR20150124A (en) 2015-04-24
BR112015004091A2 (en) 2017-07-04
CN104602678A (en) 2015-05-06
TW201414511A (en) 2014-04-16
RU2015111523A (en) 2016-10-20
EP2890371A1 (en) 2015-07-08
NI201500028A (en) 2017-01-04
AR092385A1 (en) 2015-04-22
US20150231085A1 (en) 2015-08-20
MX2015002591A (en) 2015-06-10
AU2013309688A1 (en) 2015-02-26
WO2014035190A1 (en) 2014-03-06
IL237425A0 (en) 2015-04-30
CA2882738A1 (en) 2014-03-06
MA37953A1 (en) 2017-01-31
SG11201500580QA (en) 2015-02-27
ECSP15010617A (en) 2015-12-31
EA201590474A1 (en) 2015-06-30
ZA201502157B (en) 2016-10-26
PE20150402A1 (en) 2015-04-13
JP2015526509A (en) 2015-09-10
KR20140030505A (en) 2014-03-12
CL2015000363A1 (en) 2015-06-05
EP2890371A4 (en) 2016-04-06

Similar Documents

Publication Publication Date Title
PH12015500395A1 (en) Pharmaceutical composite capsule formulation comprising irbesartan and hmg-coa reductase inhibitor
SG194756A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
MY157307A (en) Pharmaceutical formulation in the form of bilayered tablets comprising hmg-coa reductase inhibitor and irbersartan
RU2573392C3 (en) COMPOSITION CONTAINING TETRACYCLIC COMPOUNDS
AU2012259422A8 (en) Solid forms of a pharmaceutically active substance
RS53995B1 (en) New abuse-resistant pharmaceutical composition for the treatment of opioid dependence
IN2014MN02236A (en)
EP3513789A3 (en) Prophylactic and therapeutic agents for fgfr3 diseases
WO2013112959A8 (en) Antifibrotic compounds and uses thereof
UA112764C2 (en) OPTIMIZED SYNTHESIS OF PURE, NON-POLYMORPHIC CRYSTALLIC bile acids with a predetermined particle size
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
EP3648745A4 (en) Pharmaceutical composition including multi-unit spheroidal tablet containing esomeprazole and spheroidal pharmaceutically acceptable salt thereof, and method of preparing the pharmaceutical composition
TR201001417A1 (en) Cefdinir formulation with improved dissolution rate
MX2016007741A (en) Pharmaceutical combined preparation containing hmg-coa reductase inhibitor and cholesterol absorption inhibitor.
IN2014CN02343A (en) Oral formulations containing hyaluronic acid for sustained drug release
IN2015DN02296A (en)
TN2012000568A1 (en) Sustained-release therapeutic agent for hypertension and renal dysfunction
PH12015500394A1 (en) Bilayered composite tablet formulation comprising atorvastatin, irbesartan and magnesium carbonate
WO2013057569A3 (en) Extended release pharmaceutical composition containing amoxicillin and clavulanic acid
IN2012CH03125A (en)
WO2013054178A3 (en) Extended release pharmaceutical compositions containing carmabazepine
MX2011005899A (en) Pharmaceutical composition with non-sedative antihistamine and combinations thereof.
TN2013000440A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
IN2013MU03765A (en)
MX2012014498A (en) Rosuvastatin pharmaceutical composition.